Protara Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Protara Therapeutics, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Cell therapy platform with potentially transformative efficacy in high-unmet-need bladder cancer indication backed by strong analyst upside and regulatory momentum. Analysts in good agreement that stock price will rise by 300.9%, and recent Phase 2 data demonstrates 68% complete response rates with Breakthrough Therapy designation. Currently unprofitable and not.
What is Protara Therapeutics, Inc.'s industry? Protara Therapeutics, Inc. (protaratx.com) operates in Biopharmaceuticals / Clinical-Stage Therapeutics / Cell Therapy. AskCyborg classifies Protara Therapeutics, Inc. under Biopharmaceuticals / Clinical-Stage Therapeutics / Cell Therapy in its company registry.
Protara Therapeutics is a clinical-stage biotechnology company advancing transformative therapies for cancer and rare diseases, with its lead candidate TARA-002, an investigational cell-based therapy in development fo...
Cyborg Score thesis
Cell therapy platform with potentially transformative efficacy in high-unmet-need bladder cancer indication backed by strong...
Read the full analyst-debate transcript →Get the Latest Protara Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeProtara Therapeutics, Inc. Overview
Pro stress-test →Protara Therapeutics is a clinical-stage biotechnology company advancing transformative therapies for cancer and rare diseases, with its lead candidate TARA-002, an investigational cell-based therapy in development for non-muscle invasive bladder cancer and lymphatic malformations. The company recently demonstrated a 68% complete response rate at six months in BCG-unresponsive non-muscle invasive bladder cancer.
Strategic Profile
Pro stress-test →Protara is evaluating TARA-002 in Phase 2 trials for NMIBC patients with carcinoma in situ who are unresponsive or naïve to BCG treatment, and in pediatric patients with lymphatic malformations. The company is also developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support.
Competitive Landscape
Pro stress-test →Protara competes in the rare disease and bladder cancer therapeutics space against other cell therapy and immunotherapy developers. Key competitors include other clinical-stage cell therapy platforms targeting similar indications, though TARA-002's localized cell therapy approach differentiates it from systemic immunotherapies and checkpoint inhibitors.
Industry Context
Protara Therapeutics, Inc. operates in Biopharmaceuticals / Clinical-Stage Therapeutics / Cell Therapy.
Key facts
Headquarters: New York, United States